These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8977702)

  • 61. Painful Oral Ulcers With Lymphadenopathy and Respiratory Symptoms: Challenge.
    Hemminger J; Salavaggione AL; Allen C; Gru AA
    Am J Dermatopathol; 2016 Jul; 38(7):533-5. PubMed ID: 27322788
    [No Abstract]   [Full Text] [Related]  

  • 62. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins].
    Szép Z; Danilla T; Buchvald D
    Cas Lek Cesk; 2005; 144(10):700-3. PubMed ID: 16279438
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pemphigus vulgaris successfully treated with cyclophosphamide.
    Ebringer A; Mackay IR
    Ann Intern Med; 1969 Jul; 71(1):125-7. PubMed ID: 5791089
    [No Abstract]   [Full Text] [Related]  

  • 65. Pemphigus vulgaris in three adolescents: the course of the disease.
    Popadic S; Medenica L; Skiljevic D; Djakovic Z; Nikolic M
    Australas J Dermatol; 2011 Aug; 52(3):e3-7. PubMed ID: 21834807
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide.
    Pandya AG; Sontheimer RD
    Arch Dermatol; 1992 Dec; 128(12):1626-30. PubMed ID: 1456758
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Successful use of cyclophosphamide and prednisone for initial treatment of pemphigus vulgaris.
    Fellner MJ; Katz JM; McCabe JB
    Arch Dermatol; 1978 Jun; 114(6):889-94. PubMed ID: 666324
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interventions for pemphigus vulgaris and pemphigus foliaceus.
    Martin LK; Werth V; Villanueva E; Segall J; Murrell DF
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006263. PubMed ID: 19160272
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Paraneoplastic pemphigus: two cases of intra-abdominal malignancy presenting solely as treatment refractory oral ulceration.
    Kelly S; Schifter M; Fulcher DA; Lin MW
    J Dermatol; 2015 Mar; 42(3):300-4. PubMed ID: 25557248
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Etiology of pyrexia in pemphigus patients: a dermatologist's enigma.
    Qadim HH; Hasani A; Zinus BM; Orang NJ; Hasani A
    Indian J Dermatol Venereol Leprol; 2012; 78(6):774. PubMed ID: 23075657
    [No Abstract]   [Full Text] [Related]  

  • 71. Outcome of pemphigus vulgaris.
    Kavusi S; Daneshpazhooh M; Farahani F; Abedini R; Lajevardi V; Chams-Davatchi C
    J Eur Acad Dermatol Venereol; 2008 May; 22(5):580-4. PubMed ID: 18194237
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Enlarging ulcers in the mouth and on the back. Granulomatosis with polyangiitis.
    Massone C; Felletti R; Noto S; Pelucco D; Bandelloni R; Barabino G
    Am J Dermatopathol; 2015 Apr; 37(4):293-4, 341-2. PubMed ID: 25794370
    [No Abstract]   [Full Text] [Related]  

  • 73. [Pemphigus].
    Lapeyre-Liénard H; Joly P
    Presse Med; 2010 Oct; 39(10):1066-70. PubMed ID: 20817387
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A resistant case of pemphigus gestationis successfully treated with intravenous immunoglobulin plus cyclosporine.
    Hapa A; Gurpinar A; Akan T; Gokoz O
    Int J Dermatol; 2014 Apr; 53(4):e269-71. PubMed ID: 23879601
    [No Abstract]   [Full Text] [Related]  

  • 75. Pemphigus vulgaris treated with adalimumab: case study.
    Vojáčková N; Fialová J; Vaňousová D; Hercogová J
    Dermatol Ther; 2012; 25(1):95-7. PubMed ID: 22591504
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Penile erosions as first manifestation of pemphigus vulgaris: a misleading presentation.
    Stieger M; Pelivani N; Ramelet AA; Beltraminelli H; Borradori L
    Acta Derm Venereol; 2013 Mar; 93(2):248-9. PubMed ID: 22735689
    [No Abstract]   [Full Text] [Related]  

  • 77. Identification of factors associated with treatment refractoriness of oral lesions in pemphigus vulgaris.
    Kumar S; De D; Handa S; Ratho RK; Bhandari S; Pal A; Kamboj P; Sarkar S
    Br J Dermatol; 2017 Dec; 177(6):1583-1589. PubMed ID: 28498563
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [When is it possible to discontinue therapy in pemphigus vulgaris?].
    Mashkilleyson N; Eskelinen A
    Z Hautkr; 1986 Nov; 61(22):1596-602. PubMed ID: 3101298
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris.
    Hayag MV; Cohen JA; Kerdel FA
    J Am Acad Dermatol; 2000 Dec; 43(6):1065-9. PubMed ID: 11100024
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rituximab for pemphigus vulgaris.
    Joly P; D'Incan M; Musette P
    N Engl J Med; 2007 Feb; 356(5):521; author reply 521-2. PubMed ID: 17267915
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.